Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901539 | 0.90 | L3MBTL1 (0.47) | L3MBTL1GAAMAPTALDH1A1PDE3B | |
| SCHEMBL14901534 | 0.87 | L3MBTL1 (0.53) | L3MBTL1GAAPPARAMAPTPPARG | |
| SCHEMBL14901538 | 0.86 | L3MBTL1 (0.44) | L3MBTL1GAAMAPTALDH1A1PDE3B | |
| SCHEMBL10030181 | 0.86 | L3MBTL1 (0.55) | L3MBTL1GAAMAPTALDH1A1PDE3B | |
| SCHEMBL27495385 | 0.85 | ALDH1A1 (0.47) | L3MBTL1GAAMAPTALDH1A1RAB9A | |
| SCHEMBL12516025 | 0.84 | AR (0.54) | L3MBTL1GAAMAPTALDH1A1 | |
| SCHEMBL28492938 | 0.81 | CYP1A2 (0.54) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL9118684 | 0.80 | L3MBTL1 (0.50) | L3MBTL1GAAMAPTALDH1A1PDE3B | |
| SCHEMBL10030195 | 0.80 | L3MBTL1 (0.59) | L3MBTL1GAAMAPTALDH1A1PDE3B | |
| SCHEMBL12517382 | 0.80 | LTA4H (0.56) | LTA4HPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | L3MBTL1 2335/4885LTA4H 2660/4885GAA 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.